Logotype for Vivos Therapeutics Inc

Vivos Therapeutics (VVOS) Proxy filing summary

Event summary combining transcript, slides, and related documents.

Logotype for Vivos Therapeutics Inc

Proxy filing summary

21 Oct, 2026

Executive summary

  • Virtual annual meeting scheduled for December 2, 2026; October 9, 2026 record date, with 33,609,393 common shares outstanding and one vote per share.

  • Ten proposals include director elections, executive pay and auditor votes, a reverse split, approvals for preferred-stock conversions and issuances, an equity-plan increase, and conversion to Nevada.

Voting matters and shareholder proposals

  • Board recommends FOR all seven director nominees and Proposals 2, 4–10; recommends a 3-year frequency for future say-on-pay votes.

  • Proposal 5 seeks authority for a 1-for-20 to 1-for-40 reverse split; Board would set the ratio and timing and may abandon it before effectiveness.

  • Proposal 6 seeks Nasdaq approval for up to 18,476,959 shares tied to Seneca-affiliated Series A preferred stock and warrants; potential issuance is ~55% of record-date common shares.

  • Proposal 7 seeks approval for up to 80 million shares on Series C conversion; Proposal 8 would add 4.9 million shares to the equity plan, raising its reserve from 4.1 million to 9 million.

  • Proposal 9 seeks conversion from Delaware to Nevada; Proposal 10 authorizes adjournment, if needed, to solicit votes on Proposals 5–9.

Board of directors and corporate governance

  • Seven nominees stand for election through the 2027 annual meeting; six directors are independent. R. Kirk Huntsman serves as both Chair and CEO; no lead independent director is designated.

  • Standing committees are Audit, Compensation, and Nominating and Corporate Governance; each operates under a written charter, and independent directors hold executive sessions.

  • In FY2025, the Board met eight times, Audit five times, Compensation five times, and Nominating and Corporate Governance did not meet; each then-serving director attended at least 75% of applicable meetings.

  • Nevada conversion would preserve one vote per common share, written consent, the 15% special-meeting right, an unclassified Board, and existing capital authorization; internal-affairs forum would shift to Nevada.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Vivos Therapeutics